


Curriculum Vitae

 Photo	Name <small>(First Name, Middle Name Last Name)</small>	JAE HEE CHEON
	Position	Professor
	Affiliation	Yonsei University College of Medicine
	Country	Korea
	Major Field	IBD, intestinal Behcet's disease

Education Background
M.D. – Seoul National University College of Medicine, Seoul, Korea, 1996, Medicine (license No.: 59883) M.S. - Seoul National University College of Medicine, Seoul, Korea, 2001, Internal Medicine Ph.D. - Seoul National University College of Medicine, Seoul, Korea, 2006, Internal Medicine
Professional Experience
2006-2007.2 Instructor of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 2007.3-2011.2 Assistant Professor, Yonsei University College of Medicine, Seoul, Korea 2011.3-2016.2 Associate Professor, Yonsei University College of Medicine, Seoul, Korea 2011.8-2012.7 Visiting scientist, Mucosal Immunology Section, International Vaccine Institute, Seoul, Korea 2016.3-present, Professor, Yonsei University College of Medicine, Seoul, Korea
Professional Organizations
Deputy Editor of Intestinal Research Associate Editor of Gut and Liver Editorial Board member of Digestive Diseases and Sciences

Board of directors of Korean Society for Behçet's disease

Scientific Publication

1. Louis E, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Dignass AU, Magro F, Márquez JR, Moschen AR, Narula N, Rydzewska G, Freddi MJ, Travis SP. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. *BMJ Open Gastroenterol.* 2022 Feb;9(1):e000853.
2. Kim JS, Geum MJ, Son ES, Yu YM, Cheon JH, Kwon KH. Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis. *Gut Liver.* 2022 Feb 11. doi: 10.5009/gnl210371. **(corresponding author)**
3. Hyun J, Lee SK, Cheon JH, Yong DE, Koh H, Kang YK, Kim MH, Sohn Y, Cho Y, Baek YJ, Kim JH, Ahn JY, Jeong SJ, Yeom JS, Choi JY. Faecal microbiota transplantation reduces amounts of antibiotic resistance genes in patients with multidrug-resistant organisms. *Antimicrob Resist Infect Control.* 2022 Jan 29;11(1):20.
4. Dignass AU, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Travis SPL. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. *Scand J Gastroenterol.* 2021 Dec 21:1-8.
5. Park JS, Park JW, Shin S, Lee ST, Shin SJ, Min BS, Park SJ, Park JJ, Cheon JH, Kim WH, Kim TI. Application of Multigene Panel Testing In Patients With High Risk for Hereditary Colorectal Cancer: A Descriptive Report Focused On Genotype-Phenotype Correlation. *Dis Colon Rectum.* 2021 Dec 9. doi: 10.1097/DCR.0000000000002039. Online ahead of print.
6. Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. *Lancet Gastroenterol Hepatol.* 2022 Feb;7(2):118-127.
7. Kim ER, Park JS, Kim JH, Oh JY, Oh IJ, Choi DH, Lee YS, Park IS, Kim S, Lee DH, Cheon JH, Bae JW, Lee M, Cho JW, An IB, Nam EJ, Yang SI, Lee MS, Bae SH, Lee YH. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. *Hepatology.* 2021 Nov 12. doi: 10.1002/hep.32235. Online ahead of print.
8. Park J, Kim DH, Kim S, Ma HW, Park IS, Son M, Kim JH, Shin Y, Kim SW, Cheon JH. Anti-inflammatory properties of *Escherichia coli* Nissle 1917 in a murine colitis model. *Intest Res.* 2021 Oct;19(4):478-481. (corresponding author)
9. Hyun HK, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Radiology plus ileocolonoscopy versus radiology alone in Crohn's disease: prognosis prediction and mutual agreement. *Korean J Intern Med.* 2021 Oct 26. doi: 10.3904/kjim.2021.233. Online ahead of print. (corresponding author)
10. Kang EA, Park JW, Park Y, Park SJ, Kim TI, Kim WH, Cho MS, Cheon JH. C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet's disease. *BMC Gastroenterol.* 2021 Oct 7;21(1):362. (corresponding author)
11. Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, Yazici H. Behçet syndrome. *Nat Rev Dis Primers.* 2021 Sep 16;7(1):67.
12. Park J, Cheon JH. Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease? *Gut Liver.* 2021 Sep 15;15(5):641-642. doi: 10.5009/gnl210345. (corresponding author)
13. Yu J, Hyun HK, Park J, Kang EA, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Continued Postoperative Use of Tumor Necrosis Factor- α Inhibitors for the Prevention of Crohn's Disease Recurrence. *Gut Liver.* 2021 Aug 24. doi: 10.5009/gnl210062. Online ahead of print. (corresponding author)
14. Fremder M, Kim SW, Khamaysi A, Shimshilashvili L, Eini-Rider H, Park IS, Hadad U, Cheon JH, Ohana E. A transepithelial pathway delivers succinate to macrophages, thus perpetuating their pro-inflammatory metabolic state. *Cell Rep.* 2021 Aug 10;36(6):109521. (corresponding author)

15. Kim DH, Park J, Kim S, Yoon MY, Ma HW, Park IS, Son M, Kim JH, Kim TI, Kim WH, Yoon SS, Kim SW, Cheon JH. An Escherichia coli strain with extra catalase activity protects against murine colitis by scavenging hydrogen peroxide and regulating regulatory T cell/interleukin-17 pathways. *Free Radic Biol Med.* 2021 Oct;174:110-120. (Correspondence author)
16. Park J, Park S, Lee SA, Park SJ, Cheon JH. Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management. *Korean J Intern Med.* 2021 Sep;36(5):1040-1048. (corresponding author)
17. Park JW, Chang SY, Lim JS, Park SJ, Park JJ, Cheon JH, Kim WH, Kim TI. Impact of Visceral Fat on Survival and Metastasis of Stage III Colorectal Cancer. *Gut Liver.* 2022 Jan 15;16(1):53-61.
18. Ye BD, Cheon JH, Song KH, Kim JS, Kim YH, Yoon H, Lee KM, Kang SB, Jang BI, Park JJ, Kim TO, Lee DW, Foo CY, Shin JE, Park DI. The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study. *Therap Adv Gastroenterol.* 2021 Jul 5;14:17562848211024769
19. Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, Kim SH, Jung NH, Park JE, Lee YJ, Jeon DB, Lee YM, Kim JM, Park SH. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness. *Adv Ther.* 2021 Aug;38(8):4366-4387. (1st author)
20. Kim B, Chae J, Kim EH, Yang HI, Cheon JH, Kim TI, Kim WH, Jeon JY, Park SJ. Physical activity and quality of life of patients with inflammatory bowel disease. *Medicine (Baltimore).* 2021 Jul 9;100(27):e26290.
21. Park J, Jeong D, Chung YW, Han S, Kim DH, Yu J, Cheon JH, Ryu JH. Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet's disease from Crohn's disease. *Sci Rep.* 2021 May 26;11(1):11019. (corresponding author)
22. Park JW, Jeong JM, Cho KS, Cho SY, Cheon JH, Choi DH, Park SJ, Kim HK. MiR-30a and miR-200c differentiate cholangiocarcinomas from gastrointestinal cancer liver metastases. *PLoS One.* 2021 Apr 14;16(4):e0250083.
23. Kim JM, Rim JH, Kim DH, Kim HY, Choi SK, Kim DY, Choi YJ, Yu S, Cheon JH, Gee HY. Microbiome analysis reveals that *Ralstonia* is responsible for decreased renal function in patients with ulcerative colitis. *Clin Transl Med.* 2021 Mar;11(3):e322. (corresponding author)
24. Seo DH, Che X, Kim S, Kim DH, Ma HW, Kim JH, Kim TI, Kim WH, Kim SW, Cheon JH. Triggering Receptor Expressed on Myeloid Cells-1 Agonist Regulates Intestinal Inflammation via Cd177+ Neutrophils. *Front Immunol.* 2021 Mar 9;12:650864. (corresponding author)
25. Yu J, Park J, Kang EA, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis. *Gut Liver.* 2021 Nov 15;15(6):858-866. (corresponding author)
26. Degenhardt F, Mayr G, Wendorff M, International IBD Genetics Consortium, et al. Trans-ethnic analysis of the human leukocyte antigen region for ulcerative colitis reveals shared but also ethnicity-specific disease associations. *Hum Mol Genet.* 2021 Feb 8;30:ddab017.
27. Yoon JY, Cha JM, Lee CK, et al. Early course of newly diagnosed moderate-to-severe ulcerative colitis in Korea: Results from a hospital-based inception cohort study (MOSAIC). *J Gastroenterol Hepatol.* 2021 Feb 8. doi: 10.1111/jgh.15435. Online ahead of print.
28. Kim JM, Kang JG, Kim S, Cheon JH. Deep-learning system for real-time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis. *J Gastroenterol Hepatol.* 2021 Feb 7. doi: 10.1111/jgh.15433. Online ahead of print. **(Correspondence author)**
29. Kim B, Seo Y, Kwon JH, et al. IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor. *Mol Carcinog.* 2021 Mar;60(3):188-200.
30. Park J, Cheon JH. Incidence and Prevalence of Inflammatory Bowel Disease across Asia. *Yonsei Med J.* 2021 Feb;62(2):99-108. **(Correspondence author)**
31. Kim YI, Yi EJ, Kim YD, Lee AR, Chung J, Ha HC, Cho JM, Kim SR, Ko HJ, Cheon JH, Hong YR, Chang SY. Local Stabilization of Hypoxia-Inducible Factor-1 α Controls Intestinal Inflammation via Enhanced Gut Barrier Function and Immune Regulation. *Front Immunol.* 2021 Jan 14;11:609689.

32. Park JJ, Kim BC, Hong SP, et al. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis. *Cancer Prev Res (Phila)*. 2021 Jan 28. doi: 10.1158/1940-6207.CAPR-20-0580. Online ahead of print.
33. Park YE, Park SJ, Park JJ, et al. Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet's disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin. *BMC Gastroenterol*. 2021 Jan 21;21(1):32.
34. Jeong SH, Choi JS, Kim JW, et al. Clinical Features of Intra-Abdominal Abscess and Intestinal Free-Wall Perforation in Korean Patients with Crohn's Disease: Results from the CONNECT Study. *J Clin Med*. 2020 Dec 31;10(1):116.
35. Kim HM, Kim JW, Kim HS, et al. Effect of Thiopurine on Potential Surgical Intervention in Crohn's Disease in Korea: Results from the CONNECT Study. *J Clin Med*. 2020 Dec 23;10(1):25.
36. Kim MA, Kim YH, Chun J, et al. The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: A systematic review and meta-analysis. *J Crohns Colitis*. 2020 Nov 11;jjaa225.
37. Park IS, Son M, Ma HW, Kim J, Kim DH, Kim SW, Cheon JH. Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice. *Intest Res*. 2020 Nov 2. doi: 10.5217/ir.2020.00075. Online ahead of print. **(Correspondence author)**
38. Park J, Jeong D, Chung YW, Kim DH, Cheon JH, Ryu JH. Quantitative Proteomic Analysis of the Expression of SARS-CoV-2 Receptors in the Gut of Patients with Chronic Enterocolitis. *Yonsei Med J*. 2020 Oct;61(10):891-894. **(Correspondence author)**
39. Kim JM, Kim DH, Park HJ, Ma HW, Park IS, Son M, Ro SY, Hong S, Han HK, Lim SJ, Kim SW, Cheon JH. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. *J Nanobiotechnology*. 2020 Sep 15;18(1):133. **(Correspondence author)**
40. Seong H, Lee SK, Cheon JH, Yong DE, Koh H, Kang YK, Jeong WY, Lee WJ, Sohn Y, Cho Y, Hyun JH, Baek YJ, Kim MH, Kim JH, Ahn JY, Ku NS, Jeong SJ, Yeom JS, Cho MS, Lee JH, Kim BY, Choi JY. Fecal Microbiota Transplantation for multidrug-resistant organism: Efficacy and Response prediction. *J Infect*. 2020 Sep 11;4834.
41. Seo Y, Kim J, Park SJ, Park JJ, Cheon JH, Kim WH, Kim TI. Metformin Suppresses Cancer Stem Cells through AMPK Activation and Inhibition of Protein Prenylation of the Mevalonate Pathway in Colorectal Cancer. *Cancers (Basel)*. 2020 Sep 8;12(9):E2554.
42. Jung YS, Han M, Park S, Cheon JH. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease. *Gut Liver*. 2020 Aug 26. **(Correspondence author)**
43. Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis. *Gut Liver*. 2020 Jul 6. **(Correspondence author)**
44. Chang JY, Kim JH, Kang J, Park Y, Park SJ, Cheon JH, Kim WH, Kim H, Park JJ, Kim TI. mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer. *Yonsei Med J*. 2020 Jul;61(7):572-578.
45. Han M, Jung YS, Cheon JH, Park S. Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study. *Yonsei Med J*. 2020 May;61(5):382-390. **(Correspondence author)**
46. Kim JM, Park JW, Lee JH, Park YH, Park SJ, Cheon JH, Kim WH, Kim TI. Survival Benefit for Metformin Through Better Tumor Response by Neoadjuvant Concurrent Chemoradiotherapy in Rectal Cancer. *Dis Colon Rectum*. 2020 Jun;63(6):758-768.
47. Jung YS, Han M, Park S, Cheon JH. Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study. *Korean J Intern Med*. 2020 Sep;35(5):1104-1113. **(Correspondence author)**
48. Kim JM, Cheon JH. Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. *Intest Res*. 2020 Jul;18(3):249-264. doi: 10.5217/ir.2019.00128. Epub 2020 Apr 18. **(Correspondence author)**
49. Park Y, Cheon JH. Update on the Treatment of Behçet's Disease of the Small Bowel with Biologic Agents. *Curr*

Gastroenterol Rep. 2020 Mar 19;22(5):24. **(Correspondence author)**

50. Kim JM, Park JW, Lee JH, Park YH, Park SJ, Cheon JH, Kim WH, Kim TI. Survival Benefit for Metformin Through Better Tumor Response By Neoadjuvant CCRT in Rectal Cancer. *Dis Colon Rectum*. 2020 Feb 26.
51. Suh JH, Park MC, Goughnour PC, Min BS, Kim SB, Lee WY, Cho YB, Cheon JH, Lee KY, Nam DH, Kim S. Plasma Lysyl-tRNA Synthetase 1 (KARS1) as a Novel Diagnostic and Monitoring Biomarker for Colorectal Cancer. *J Clin Med*. 2020 Feb 15;9(2):533.
52. Kim SW, Kim S, Son M, Cheon JH, Park YS. Melatonin controls microbiota in colitis by goblet cell differentiation and antimicrobial peptide production through Toll-like receptor 4 signalling. *Sci Rep*. 2020 Feb 10;10(1):2232.
53. Saruta M, Park DI, Kim YH, Yang SK, Jang BI, Cheon JH, Im JP, Kanai T, Katsuno T, Ishiguro Y, Nagaoka M, Isogawa N, Li Y, Banerjee A, Ahmad A, Hassan-Zahraee M, Clare R, Gorelick KJ, Cataldi F, Watanabe M, Hibi T. Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study. *Intest Res*. 2020 Jan;18(1):45-55.
54. Kim DH, Kim S, Ahn JB, Kim JH, Ma HW, Seo DH, Che X, Park KC, Jeon JY, Kim SY, Lee HC, Lee JY, Kim TI, Kim WH, Kim SW, Cheon JH. *Lactobacillus plantarum* CBT LP3 ameliorates colitis via modulating T cells in mice. *Int J Med Microbiol*. 2020 Feb;310(2):151391.
55. Kim J, Im JP, Yim JJ, Lee CK, Park DI, Eun CS, Jung SA, Shin JE, Lee KM, Cheon JH. Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy. *Korean J Gastroenterol*. 2020 Jan 25;75(1):29-38.
56. Kim HY, Cheon JH, Lee SH, Min JY, Back SY, Song JG, Kim DH, Lim SJ, Han HK. Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization. *J Nanobiotechnology*. 2020 Jan 21;18(1):17.
57. Kim JH, Ahn JB, Kim DH, Kim S, Ma HW, Che X, Seo DH, Kim TI, Kim WH, Cheon JH, Kim SW. Glutathione S-transferase theta 1 protects against colitis through goblet cell differentiation via interleukin-22. *FASEB J*. 2020 Feb;34(2):3289-3304.
58. Han M, Jung YS, Cheon JH, Park S. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study. *Yonsei Med J*. 2020 Jan;61(1):48-55.
59. Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. *Dig Dis Sci*. 2020 May;65(5):1436-1444.
60. Yang DH, Park SJ, Kim HS, Park YS, Park DI, Lee KM, Jung SA, Choi CH, Koo JS, Cheon JH, Yang SK, Kim WH, Kim J, Kim H, Ryan Choi CH; Korean Association for the Study of the Intestinal Diseases (KASID) study. High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial. *Am J Gastroenterol*. 2019 Oct;114(10):1642-1648.
61. Kim SB, Cheon JH, Park JJ, Kim ES, Jeon SW, Jung SA, Park DI, Lee CK, Im JP, Kim YS, Kim HS, Lee J, Eun CS, Lee JM, Jang BI, Seo GS. Risk Factors for Postoperative Recurrence in Korean Patients with Crohn's Disease. *Gut Liver*. 2020 May 15;14(3):331-337.
62. Moon JR, Lee CK, Hong SN, Im JP, Ye BD, Cha JM, Jung SA, Lee KM, Park DI, Jeon YT, Park YS, Cheon JH, Kim H, Seo B, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for Study of Intestinal Diseases. Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea. *Gut Liver*. 2020 Jul 15;14(4):459-467.
63. Cho MS, Kim H, Han YD, Hur H, Min BS, Baik SH, Cheon JH, Lim JS, Lee KY, Kim NK. Endoscopy and magnetic resonance imaging-based prediction of ypT stage in patients with rectal cancer who received chemoradiotherapy: Results from a prospective study of 110 patients. *Medicine (Baltimore)*. 2019 Aug;98(35):e16614.
64. Chang JY, Park SJ, Jung ES, Jung SA, Moon CM, Chun J, Park JJ, Kim ES, Park Y, Kim TI, Kim WH, Cheon JH. Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2019 Aug 22. **(Correspondence author)**
65. Lee HJ, Kim JH, Hong S, Hwang I, Park SJ, Kim TI, Kim WH, Yu JW, Kim SW, Cheon JH. Proteomics-based functional studies reveal that galectin-3 plays a protective role in the pathogenesis of intestinal Behçet's disease. *Sci Rep*. 2019

Aug 12;9(1):11716. **(Correspondence author)**

66. Park YE, Park Y, Park SJ, Kim TI, Kim WH, Kim JN, Lee NR, Cheon JH. Is fasting beneficial for hospitalized patients with inflammatory bowel diseases? *Intest Res.* 2019 Jul 19. doi: 10.5217/ir.2019.00055. [Epub ahead of print] **(Correspondence author)**
67. Chang JY, Cheon JH. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. *Dig Dis Sci.* 2019 Sep;64(9):2395-2403. **(Correspondence author)**
68. Lee HJ, Park SJ, Cheon JH, Kim TI, Kim WH, Kim HJ. The relationship between diverticulosis and colorectal neoplasia: A meta-analysis. *PLoS One.* 2019 May 29;14(5):e0216380.
69. Lee DH, Han JY, Park JJ, Cheon JH, Kim M. Ophthalmologic Manifestation of Inflammatory Bowel Disease: A Review. *Korean J Gastroenterol.* 2019 May 25;73(5):269-275.
70. Park JS, Kang B, Park Y, Park SJ, Cheon JH, Jung M, Beom SH, Shin SJ, Hur H, Min BS, Baik SH, Lee KY, Ahn JB, Kim NK, Kim TI. Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. *J Cancer Prev.* 2019 Mar;24(1):48-53.
71. Park Y, Park SJ, Cheon JH, Kim WH, Kim TI. Association of Family History With Cancer Recurrence, Survival, and the Incidence of Colorectal Adenoma in Patients With Colorectal Cancer. *J Cancer Prev.* 2019 Mar;24(1):1-10.
72. Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, Fishman S, Levchenko O, Cheon JH, Scribano ML, Mateescu RB, Lee KM, Eun CS, Lee SJ, Lee SY, Kim H, Schreiber S, Fowler H, Cheung R, Kim YH. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. *Lancet.* 2019 Apr 27;393(10182):1699-1707.
73. Cha JH, Jung DH, Kim JH, Youn YH, Park H, Park JJ, Um YJ, Park SJ, Cheon JH, Kim TI, Kim WH, Lee HJ. Long-term outcomes according to additional treatments after endoscopic resection for rectal small neuroendocrine tumors. *Sci Rep.* 2019 Mar 20;9(1):4911.
74. Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. *J Gastroenterol Hepatol.* 2019 Mar 9. doi: 10.1111/jgh.14652. [Epub ahead of print] **(Correspondence author)**
75. Han M, Jung YS, Cheon JH, Park S. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. *J Gastroenterol Hepatol.* 2019 Jul;34(7):1166-1174. **(Correspondence author)**
76. Degenhardt F, Wendorff M, Wittig M, Ellinghaus E, Datta LW, Schembri J, Ng SC, Rosati E, Hübenthal M, Ellinghaus D, Jung ES, Lieb W, Abedian S, Malekzadeh R, Cheon JH, Ellul P, Sood A, Midha V, Thelma BK, Wong SH, Schreiber S, Yamazaki K, Kubo M, Boucher G, Rioux JD, Lenz TL, Brant SR, Franke A. Construction and benchmarking of a multi-ethnic reference panel for the imputation of HLA class I and II alleles. *Hum Mol Genet.* 2019 Jun 15;28(12):2078-2092.
77. Lee SW, Park HJ, Cheon JH, Wu L, Van Kaer L, Hong S. iNKT Cells Suppress Pathogenic NK1.1(+)/CD8(+) T Cells in DSS-Induced Colitis. *Front Immunol.* 2018 Oct 2;9:2168.
78. Park JW, Kim TI, Cheon JH. Probe-based confocal laser endomicroscopy in the differential diagnosis of inflammatory bowel diseases: a case series. *Intest Res.* 2018 Oct;16(4):641-645. **(Correspondence author)**
79. Jung ES, Petersen BS, Mayr G, Cheon JH, Kang Y, Lee SJ, Che X, Kim WH, Kim S, Schreiber S, Franke A, Koh H. Compound heterozygous mutations in IL10RA combined with a complement factor properdin mutation in infantile-onset inflammatory bowel disease. *Eur J Gastroenterol Hepatol.* 2018 Dec;30(12):1491-1496.
80. Park JJ, Rhee K, Yoon JY, Park SJ, Kim JH, Kim JH, Youn YH, Kim TI, Park H, Kim WH, Cheon JH. Impact of peritoneal carcinomatosis on clinical outcomes of patients receiving self-expandable metal stents for malignant colorectal obstruction. *Endoscopy.* 2018 Dec;50(12):1163-1174. **(Correspondence author)**
81. Park YE, Park Y, Park SJ, Cheon JH, Kim WH, Kim TI. Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration. *Surg Endosc.* 2019 Apr;33(4):1225-1234.
82. Shin DS, Cheon JH, Park YE, Park Y, Park SJ, Kim TI, Kim WH. Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis. *Dig Dis Sci.* 2018 Nov;63(11):3097-3104. **(Correspondence author)**
83. Lee JH, Park YE, Seo N, Lee HJ, Park SJ, Kim TI, Kim WH, Lim JS, Cheon JH. Magnetic resonance enterography

predicts the prognosis of Crohn's disease. *Intest Res.* 2018 Jul;16(3):445-457. **(Correspondence author)**

84. Chun J, Im JP, Kim JW, et al. Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study. *Gut Liver.* 2018 Sep 15;12(5):544-554.

85. Chang JY, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation? *Dig Dis Sci.* 2018 Nov;63(11):3041-3048. **(Correspondence author)**

86. Park YE, Cheon JH, Park JJ, Kim YJ, Choi CH, Park Y, Park SJ, Kim TI, Kim WH. Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study. *Int J Colorectal Dis.* 2018 Oct;33(10):1497-1500. **(Correspondence author)**

87. Park JW, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Development of a Novel Endoscopic Scoring System to Predict Relapse after Surgery in intestinal Behçet's Disease. *Gut Liver.* 2018 Nov 15;12(6):674-681. **(Correspondence author)**

88. Kim DH, Kim S, Lee JH, Kim JH, Che X, Ma HW, Seo DH, Kim TI, Kim WH, Kim SW, Cheon JH. *Lactobacillus acidophilus* suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress. *J Gastroenterol Hepatol.* 2019 Jan;34(1):178-185. **(Correspondence author)**

89. Park J, Cheon JH. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease. *Gut Liver.* 2018 Nov 15;12(6):623-632. **(Correspondence author)**

90. Park J, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience. *Intest Res.* 2018 Apr;16(2):315-318. **(Correspondence author)**

91. Moon CM, Kim SW, Ahn JB, Ma HW, Che X, Kim TI, Kim WH, Cheon JH. Deep Resequencing of Ulcerative Colitis-Associated Genes Identifies Novel Variants in Candidate Genes in the Korean Population. *Inflamm Bowel Dis. Inflamm Bowel Dis.* 2018 Jul 12;24(8):1706-1717. **(Correspondence author)**

92. Lee HW, Park SJ, Jeon SR, Ye BD, Park JJ, Cheon JH, Kim TI, Kim WH; KASID study. Long-term outcomes of endoscopic balloon dilation for benign strictures in patients with inflammatory bowel disease. *Gut Liver.* 2018 Sep 15;12(5):530-536.

93. Lee JM, Lee KM, Kim JS, Kim YS, Cheon JH, Ye BD, Kim YH, Han DS, Lee CK, Park HJ. Postoperative course of Crohn disease according to timing of bowel resection: Results from the CONNECT Study. *Medicine (Baltimore).* 2018 Apr;97(16):e0459.

94. Kwak MS, Kim KJ, Cheon JH, Kim WS, Lee JM, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease. *Gastroenterol Res Pract.* 2018 Jan 18;2018:4826973.

95. Che X, Park KC, Park SJ, Kang YH, Jin HA, Kim JW, Seo DH, Kim DK, Kim TI, Kim WH, Kim SW, Cheon JH. The protective effects of guggulsterone against colitis are associated with the suppression of TREM-1 and modulation of macrophages. *Am J Physiol Gastrointest Liver Physiol.* 2018 Jul 1;315(1):G128-G139. **(Correspondence author)**

96. Park J, Lee HJ, Park SJ, Hur H, Min BS, Cheon JH, Kim TI, Kim NK, Kim WH. Long-term outcomes after stenting as a bridge to surgery in patients with obstructing left-sided colorectal cancer. *Int J Colorectal Dis.* 2018 Jun;33(6):799-807.

97. Park J, Kim JH, Park Y, Park SJ, Cheon JH, Kim WH, Park JS, Jeon JY, Kim TI. Resting heart rate is an independent predictor of advanced colorectal adenoma recurrence. *PLoS One.* 2018 Mar 2;13(3):e0193753.

98. Chang JY, Cheon JH. Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis. *Gut Liver.* 2018 Mar 15;12(2):117-118. **(Correspondence author)**

99. Lee YJ, Yoon JY, Park JJ, Park SJ, Kim JH, Youn YH, Kim TI, Park H, Kim WH, Cheon JH. Clinical outcomes and factors related to colonic perforations in patients receiving self-expandable metal stent insertion for malignant colorectal obstruction. *Gastrointest Endosc.* 2018 Jun;87(6):1548-1557.e1. **(Correspondence author)**

100. Han M, Jung YS, Kim WH, Cheon JH, Park S. Cancer Risk in Patients with Intestinal Behçet's Disease: A Nationwide Population-Based Study. *Gut Liver.* 2018 Jul 15;12(4):433-439 **(Correspondence author)**

101. Kim JH, Lee KJ, Seo Y, Kwon JH, Yoon JP, Kang JY, Lee HJ, Park SJ, Hong SP, Cheon JH, Kim WH, Kim TI. Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. *Sci Rep.* 2018 Jan

11;8(1):409.

102. Jung YS, Han M, Kim DY, Cheon JH, Park S. Cancer risk in Korean patients with Behçet's disease: A nationwide population-based study. *PLoS One*. 2017 Dec 29;12(12):e0190182. **(Correspondence author)**
103. Park YE, Park SJ, Park Y, Cheon JH, Kim TI, Kim WH. Impact and outcomes of nutritional support team intervention in patients with gastrointestinal disease in the intensive care unit. *Medicine (Baltimore)*. 2017 Dec;96(49):e8776.
104. Lee HJ, Hong SP, Cheon JH, Kim TI, Kim WH, Park SJ. Clinical Outcomes of Self-Expandable Metal Stents for Malignant Rectal Obstruction. *Dis Colon Rectum*. 2018 Jan;61(1):43-50.
105. Park YE, Cheon JH. Updated treatment strategies for intestinal Behçet's disease. *Korean J Intern Med*. 2018 Jan;33(1):1-19. **(Correspondence author)**
106. Park J, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. Risk Factors and Outcomes of Emergency Room Visits in Intestinal Behçet's Disease. *Digestion*. 2017 Nov 2;96(4):231-238. **(Correspondence author)**
107. Park YE, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. The outcomes and risk factors of early readmission in patients with intestinal Behçet's disease. *Clin Rheumatol*. 2018 Jul;37(7):1913-1920. **(Correspondence author)**
108. Yoon JY, Cheon JH, Park SJ, Kim TI, Kim WH. Effects of Perianal Involvement on Clinical Outcomes in Crohn's Disease over 10 Years. *Gut Liver*. 2018 May 15;12(3):297-305.
109. Kim SB, Lee HJ, Park SJ, Hong SP, Cheon JH, Kim WH, Kim TI. Comparison of Colonoscopy Surveillance Outcomes Between Young and Older Colorectal Cancer Patients. *J Cancer Prev*. 2017 Sep;22(3):159-165.
110. Jo JH, Park SJ, Cheon JH, Kim TI, Kim WH. Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease. *J Gastroenterol Hepatol*. 2018 Feb;33(2):375-379.
111. Kim OZ, Han DS, Park CH, Eun CS, Kim YS, Kim YH, Cheon JH, Ye BD, Kim JS. The Clinical Characteristics and Prognosis of Crohn's Disease in Korean Patients Showing Proximal Small Bowel Involvement: Results from the CONNECT Study. *Gut Liver*. 2018 Jan 15;12(1):67-72.
112. Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease. *Intest Res*. 2017 Jul;15(3):311-317. **(Correspondence author)**
113. Park J, Cheon JH. Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy? *Intest Res*. 2017 Jul;15(3):263-265. **(Correspondence author)**
114. Park JW, Lee JH, Park YH, Park SJ, Cheon JH, Kim WH, Kim TI. Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. *World J Gastroenterol*. 2017 Jul 28;23(28):5196-5205.
115. Jung YS, Han M, Kim WH, Park S, Cheon JH. Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study. *Dig Dis Sci*. 2017 Aug;62(8):2102-2112. **(Correspondence author)**
116. Park J, Kim JH, Lee HJ, Park SJ, Hong SP, Cheon JH, Kim WH, Park JS, Jeon JY, Kim TI. The Effects of Physical Activity and Body Fat Mass on Colorectal Polyp Recurrence in Patients with Previous Colorectal Cancer. *Cancer Prev Res (Phila)*. 2017 Aug;10(8):478-484.
117. Lee HJ, Kim JH, Kim SW, Joo HA, Lee HW, Kim YS, Park SJ, Hong SP, Kim TI, Kim WH, Kim YH, Cheon JH. Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet's Disease. *Dig Dis Sci*. 2017 Aug;62(8):1953-1962. **(Correspondence author)**
118. Lee HS, Kim SB, Lee HJ, Park SJ, Hong SP, Cheon JH, Kim WH, Kim TI. Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer. *Gastrointest Endosc*. 2018 Mar;87(3):688-694
119. Park Y, Cheon JH, Park YL, Ye BD, Kim YS, Han DS, Kim JS, Hong SN, Kim YH, Jeon SR, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases (KASID). Development of a Novel Predictive Model for the Clinical Course of Crohn's Disease: Results from the CONNECT Study. *Inflamm Bowel Dis*. 2017 Jul;23(7):1071-1079. **(Correspondence author)**
120. Seo DH, Che X, Kwak MS, Kim S, Kim JH, Ma HW, Kim DH, Kim TI, Kim WH, Kim SW, Cheon JH. Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. *Sci Rep*. 2017 Apr

12;7(1):851. **(Correspondence author)**

121. Jung YS, Han M, Park S, Kim WH, Cheon JH. Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study. *J Crohns Colitis*. 2017 Aug 1;11(8):954-962. **(Correspondence author)**
122. Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. *Immune Netw*. 2017 Feb;17(1):25-40. **(Correspondence author)**
123. Hwang SW, Kim JH, Im JP, Ye BD, Koo HS, Huh KC, Cheon JH, Kim YS, Kim YH, Han DS, Kim WH, Kim JS; Crohn's disease clinical network and cohort (CONNECT) study. Influence of Age at Diagnosis on the Clinical Characteristics of Crohn's Disease in Korea: Results from the CONNECT study. *J Gastroenterol Hepatol*. 2017 Oct;32(10):1716-1722.
124. Han MS, Lee HJ, Park SJ, Hong SP, Cheon JH, Kim WH, Kim TI. The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. *Int J Colorectal Dis*. 2017 Aug;32(8):1223-1226.
125. Jung ES, Park HJ, Kong KA, Choi JH, Cheon JH. Association study between OCTN1 functional haplotypes and Crohn's disease in a Korean population. *Korean J Physiol Pharmacol*. 2017 Jan;21(1):11-17. **(Correspondence author)**
126. Kim SW, Jung YS, Ahn JB, Shin ES, Jang HW, Lee HJ, Il Kim T, Kim DY, Bang D, Kim WH, Cheon JH. Identification of genetic susceptibility loci for intestinal Behçet's disease. *Sci Rep*. 2017 Jan 3;7:39850. **(Correspondence author)**
127. Park YE, Cheon JH, Park J, et al. The outcomes and risk factors of early reoperation after initial intestinal resective surgery in patients with intestinal Behçet's disease. *Int J Colorectal Dis*. 2017 Apr;32(4):591-594. **(Correspondence author)**
128. Han M, Jung YS, Kim WH, Cheon JH, Park S. Incidence and clinical outcomes of intestinal Behçet's disease in Korea, 2011-2014: a nationwide population-based study. *J Gastroenterol*. 2017 Aug;52(8):920-928. **(Correspondence author)**
129. Chi JH, Seo GS, Cheon JH, Lee SH. Isoliquiritigenin inhibits TNF- α -induced release of high-mobility group box 1 through activation of HDAC in human intestinal epithelial HT-29 cells. *Eur J Pharmacol*. 2017 Feb 5;796:101-109. **(Correspondence author)**
130. Park J, Cheon JH, Park YE, et al. Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behçet's disease. *Int J Colorectal Dis*. 2017 May;32(5):745-751. **(Correspondence author)**
131. Lee YJ, Cheon JH, Kim JH, Yoo S, Lee HJ, Park SJ, Hong SP, Kim TI, Kim WH. Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis. *Yonsei Med J*. 2017 Jan;58(1):144-149. **(Correspondence author)**
132. Song HJ, Moon JS, Jeon SR, et al. Diagnostic Yield and Clinical Impact of Video Capsule Endoscopy in Patients with Chronic Diarrhea: A Korean Multicenter CAPENTRY Study. *Gut Liver*. 2017 Mar 15;11(2):253-260.
133. Jang HW, Kim HS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. *Intest Res*. 2016 Oct;14(4):305-313. **(Correspondence author)**
134. Kim DH, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. Does a Pre-Training Program Influence Colonoscopy Proficiency during Fellowship? *PLoS One*. 2016 Oct 20;11(10):e0164360.
135. Cheon JH. Understanding the complications of anti-TNF therapy in East Asian patients with inflammatory bowel disease. *J Gastroenterol Hepatol*. 2017 Apr;32(4):769-777. **(Correspondence author)**
136. Kim B, Kim EH, Park SJ, Cheon JH, et al. The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: A retrospective study of 428 patients. *Medicine (Baltimore)*. 2016 Sep;95(37):e4373.
137. Kim DH, Kim B, Choi JH, et al. Tumor characteristics associated with malignant large bowel obstruction in stage IV colorectal cancer patients undergoing chemotherapy. *Int J Colorectal Dis*. 2016 Nov;31(11):1767-1774.
138. Kim HS, Cheon JH, Jung ES, et al. A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD. *Gut*. 2017 Nov;66(11):1926-1935. **(Co-1st Author)**

139. Kim DH, Park Y, Kim B, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet's disease. *J Gastroenterol Hepatol.* 2017 Mar;32(3):595-601. **(Correspondence author)**
140. Kim B, Choi AR, Park SJ, et al. Long-Term Outcome and Surveillance Colonoscopy after Successful Endoscopic Treatment of Large Sessile Colorectal Polyps. *Yonsei Med J.* 2016 Sep;57(5):1106-14.
141. Kim B, Kim YH, Park SJ, et al. Probe-based confocal laser endomicroscopy for evaluating the submucosal invasion of colorectal neoplasms. *Surg Endosc.* 2017 Feb;31(2):594-601
142. Lee HW, Chung SH, Moon CM, et al. The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease. *Medicine (Baltimore).* 2016 Jun;95(23):e3772. **(Correspondence author)**
143. Lee HJ, Oh SH, Jang HW, et al. Long-Term Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Dextran Sulfate Sodium-Induced Murine Chronic Colitis. *Gut Liver.* 2016 May 23;10(3):412-9.
144. Yang JY, Kim MS, Kim E, Cheon JH, et al. Enteric Viruses Ameliorate Gut Inflammation via Toll-like Receptor 3 and Toll-like Receptor 7-Mediated Interferon- β Production. *Immunity.* 2016 Apr 19;44(4):889-900. Epub 2016 Apr 12. **(co-1st author)**
145. Kwon JH, Im JP, Ye BD, et al. Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study. *Gut Liver.* 2016 Jul 15;10(4):595-603.
146. Park HJ, Jung ES, Kong KA, et al. Identification of OCTN2 variants and their association with phenotypes of Crohn's disease in a Korean population. *Sci Rep.* 2016 Mar 11;6:22887. **(co-Correspondence author)**
147. Kim JH, Cheon JH. Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis. *Gut Liver.* 2016 Mar 23;10(2):162-3. **(Correspondence author)**
148. Kim YI, Lee BR, Cheon JH, et al. Compensatory roles of CD8+ T cells and plasmacytoid dendritic cells in gut immune regulation for reduced function of CD4+ Tregs. *Oncotarget.* 2016 Feb 19. **(co-1st author)**
149. Kim JH, Cheon JH, Park Y, et al. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. *Scand J Gastroenterol.* 2016 Feb 19:1-6. **(Correspondence author)**
150. Jung ES, Cheon JH, Lee JH, et al. HLA-C*01 is a Risk Factor for Crohn's Disease. *Inflamm Bowel Dis.* 2016 Apr;22(4):796-806. **(co-1st author)**
151. Chung SH, Lee HW, Kim SW, et al. Usefulness of Measuring Serum Procalcitonin Levels in Patients with Inflammatory Bowel Disease. *Gut Liver.* 2016 Jan 19. **(Correspondence author)**
152. Moon CM, Jung SA, Kim SE, et al. Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn's Disease Patients: Results from the CONNECT Study. *PLoS One.* 2015 Dec 8;10(12)
153. Kim DH, Cheon JH. Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis? *Yonsei Med J.* 2016 Jan;57(1):22-32. **(Correspondence author)**
154. Kim B, Park SJ, Hong SP, Cheon JH, et al. The effect of prediagnostic aspirin use on the prognosis of stage III colorectal cancer. *Int J Clin Exp Med.* 2015 Aug 15;8(8):13435-45.
155. Lim YJ, Lee OY, Jeon YT, et al. Indications for Detection, Completion, and Retention Rates of Small Bowel Capsule Endoscopy Based on the 10-Year Data from the Korean Capsule Endoscopy Registry. *Clin Endosc.* 2015 Sep;48(5):399-404
156. Sohn IW, Kim ST, Kim B, et al. Efficacy of Adalimumab in Korean Patients with Crohn's Disease. *Gut Liver.* 2015 Oct 19. **(Correspondence author)**
157. Jang HW, Park SJ, Hong SP, et al. Risk Factors for Recurrent High-Risk Polyps after the Removal of High-Risk Polyps at Initial Colonoscopy. *Yonsei Med J.* 2015 Nov;56(6):1559-65.
158. Kim B, Cheon JH, Moon HJ, et al. Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study. *J Gastroenterol Hepatol.* 2015 Sep 25.
159. Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. *Expert Rev Gastroenterol Hepatol.* 2015;9 Suppl 1:35-44.
160. Lee JH, Cheon JH, Hong SP, et al. Seasonal Variation in Flares of Intestinal Behçet's Disease. *Dig Dis Sci.* 2015

Nov;60(11):3373-8. **(Correspondence author)**

161. Lee HW, Cheon JH, Lee HJ, et al. Postoperative Effects of Thiopurines in Patients with Intestinal Behçet's Disease. *Dig Dis Sci.* 2015 Dec;60(12):3721-7. **(Correspondence author)**
162. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet.* 2015 Sep;47(9):979-86
163. Park S, Noh YH, Rha SY, Kim WH, Cheon JH. Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study. *Intest Res.* 2015 Jul;13(3):274-81. **(Correspondence author)**
164. Cheon JH. Advances in the Endoscopic Assessment of Inflammatory Bowel Diseases: Cooperation between Endoscopic and Pathologic Evaluations. *J Pathol Transl Med.* 2015 May;49(3):209-17. **(1st author)**
165. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. *J Gastroenterol Hepatol.* 2015 May 14
166. Park Y, Jeon TJ, Park JY, et al. Comparison of clipping with and without epinephrine injection for the prevention of post-polypectomy bleeding in pedunculated colon polyps. *J Gastroenterol Hepatol.* 2015 Oct;30(10):1499-506.
167. Kim B, Park SJ, Hong SP, et al. Overlooked Management and Risk Factors for Anemia in Patients with Intestinal Behçet's Disease in Actual Clinical Practice. *Gut Liver.* 2015 Nov 23;9(6):750-5.
168. Doh YS, Kim YS, Bae SI, et al. The clinical characteristics of patients with free perforation in Korean Crohn's disease: results from the CONNECT study. *BMC Gastroenterol.* 2015 Mar 18;15:31
169. Chung SH, Park SU, Cheon JH, et al. Clinical Characteristics and Treatment Outcomes of Cryptogenic Multifocal Ulcerous Stenosing Enteritis in Korea. *Dig Dis Sci* 2015. **(Correspondence author)**
170. Yang SK, Hong M, Choi H, et al. Immunochip analysis identification of 6 additional susceptibility loci for Crohn's disease in Koreans. *Inflamm Bowel Dis* 2015; 21:1-7.
171. Lee S, Lee TA, Lee E, et al. Identification of a subnuclear body involved in sequence-specific cytokine RNA processing. *Nat Commun* 2015; 6:5791.
172. Jung YS, Park DI, Ye BD, et al. Long-term Clinical Outcomes of Urban Versus Rural Environment in Korean Patients with Crohn's Disease: Results from the CONNECT Study. *J Crohns Colitis* 2015; 9:246-251.
173. Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease. *Curr Opin Rheumatol* 2015; 27:24-31. **(1st author)**
174. Chang S, Cheon JH. A clinical significance of assessing cytomegalovirus infection status in patients with ulcerative colitis. *Intest Res* 2015; 13:2-3. **(Correspondence author)**
175. Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. *Scand J Gastroenterol* 2015; 50:312-320.
176. Shim KN, Song EM, Jeon YT, et al. Long-Term Outcomes of NSAID-Induced Small Intestinal Injury Assessed by Capsule Endoscopy in Korea: A Nationwide Multicenter Retrospective Study. *Gut Liver* 2014.
177. Lee BR, Chang SY, Hong EH, et al. Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells. *Oncotarget* 2014; 5:12331-12345. **(Correspondence author)**
178. Kim EH, Kim DH, Park SJ, et al. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. *Gut Liver* 2014. **(Correspondence author)**
179. Chung SH, Park SJ, Lee HS, et al. Similar clinical characteristics of familial and sporadic inflammatory bowel disease in South Korea. *World J Gastroenterol* 2014; 20:17120-17126. **(Correspondence author)**
180. Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. *Dig Dis Sci* 2014;59:829-837. **(corresponding author)**
181. Yoon JY, Park SJ, Cheon JH. Effect of Colostrum on the Symptoms and Mucosal Permeability in Patients with Irritable Bowel Syndrome: A Randomized Placebo-controlled Study. *Intestinal Res* 2014;12(1):80-82. **(corresponding author)**

author)

182. Yim SM, Kim DH, Lee HJ, et al. Mucosal healing predicts the long-term prognosis of intestinal Behcet's disease. *Dig Dis Sci* 2014;59:2529-2535. **(corresponding author)**
183. Yang SK, Hong M, Zhao W, et al. Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. *Gut* 2014;63:80-87.
184. van Halsema EE, van Hooft JE, Small AJ, et al. Perforation in colorectal stenting: a meta-analysis and a search for risk factors. *Gastrointest Endosc* 2014;79:970-982.e977; quiz 983.e972, 983.e975.
185. Seo GS, Jiang WY, Park PH, Sohn DH, Cheon JH, Lee SH. Hirsutenone reduces deterioration of tight junction proteins through EGFR/Akt and ERK1/2 pathway both converging to HO-1 induction. *Biochem Pharmacol* 2014;90:115-125. **(corresponding author)**
186. Park W, Kim B, Park SJ, et al. Conventional endoscopic features are not sufficient to differentiate small, early colorectal cancer. *World J Gastroenterol* 2014;20:6586-6593.
187. Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. *World J Gastroenterol* 2014;20:11525-11537. **(corresponding author)**
188. Park MS, Kim DH, Kim DH, et al. Leukopenia Predicts Remission in Patients with Inflammatory Bowel Disease and Behcet's Disease on Thiopurine Maintenance. *Dig Dis Sci* 2015;60(1):195-2014. **(corresponding author)**
189. Park JJ, Kwon JH, Oh SH, et al. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer. *Mol Carcinog* 2014;53 Suppl 1:E1-10.
190. Park CH, Yoon JY, Park SJ, et al. Clinical Efficacy of Endoscopic Treatment for Benign Colorectal Stricture: Balloon Dilatation versus Stenting. *Gut Liver* 2014.
191. Moon CM, Kwon JH, Kim JS, et al. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. *Int J Cancer* 2014;134:519-529.
192. Lee S, Park SJ, Cheon JH, et al. Child-Pugh score is an independent risk factor for immediate bleeding after colonoscopic polypectomy in liver cirrhosis. *Yonsei Med J* 2014;55:1281-1288.
193. Lee HJ, Shin HS, Jang HW, et al. Correlation between soluble triggering receptor expressed on myeloid cells-1 and endoscopic activity in intestinal Behcet's disease. *Yonsei Med J* 2014;55:960-966. **(corresponding author)**
194. Lee HJ, Park SJ, Min BS, et al. The role of primary colectomy after successful endoscopic stenting in patients with obstructive metastatic colorectal cancer. *Dis Colon Rectum* 2014;57:694-699.
195. Lee HJ, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. What is the necessity of endoscopist for successful endoscopic stenting in patients with malignant colorectal obstruction? *Int J Colorectal Dis* 2014.
196. Kwak MS, Kim DH, Park SJ, et al. Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease. *BMC Gastroenterol* 2014;14:85. **(corresponding author)**
197. Kim YS, Kim YH, Kim JS, et al. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. *Gut Liver* 2014;8:643-647.
198. Kim SB, Park SJ, Chung SH, et al. Vaccination and complementary and alternative medicine in patients with inflammatory bowel disease. *Intestinal Res* 2014;12:124-130.
199. Kim HH, Kim YS, Han DS, et al. Clinical differences in *Clostridium difficile* infection based on age: a multicenter study. *Scand J Infect Dis* 2014;46:46-51.
200. Kim DH, Park SJ, Park JJ, et al. Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease. *Dig Dis Sci* 2014;59:2514-2522. **(corresponding author)**
201. Kim DH, Lee JH, Cha YJ, et al. Surveillance strategy for rectal neuroendocrine tumors according to recurrence risk stratification. *Dig Dis Sci* 2014;59:850-856.
202. Kim B, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Proximal disease extension and related predicting factors in ulcerative proctitis. *Scand J Gastroenterol* 2014;49:177-183. **(corresponding author)**
203. Kim B, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. Clinical meaning of BRAF mutation in Korean patients with

advanced colorectal cancer. *World J Gastroenterol* 2014;20:4370-4376.

204. Jung YS, Park DI, Moon CM, et al. Radiation exposure from abdominal imaging studies in patients with intestinal Behcet disease. *Gut Liver* 2014;8:380-387. **(corresponding author)**
205. Jung YS, Park DI, Hong SN, et al. Predictors of Urgent Findings on Abdominopelvic CT in Patients with Crohn's Disease Presenting to the Emergency Department. *Dig Dis Sci* 2014.
206. Jang HW, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. Does magnifying narrow-band imaging or magnifying chromoendoscopy help experienced endoscopists assess invasion depth of large sessile and flat polyps? *Dig Dis Sci* 2014;59:1520-1528.
207. Cheon JH, Kim YS, Ye BD, et al. Crohn's Disease Clinical Network and Cohort (CONNECT) Study: The First Step Toward Nationwide Multicenter Research of Crohn's Disease in Korea. *Intestinal Res* 2014;12:173-175. **(1st author)**
208. Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Outcomes of secondary self-expandable metal stents versus surgery after delayed initial palliative stent failure in malignant colorectal obstruction. *Digestion* 2013;88:46-55. **(corresponding author)**
209. Park YH, Chung WS, Lim JS, et al. Diagnostic role of computed tomographic enterography differentiating crohn disease from intestinal tuberculosis. *J Comput Assist Tomogr* 2013;37:834-839.
210. Park MS, Kim WJ, Huh JH, et al. Crohn's duodeno-colonic fistula preoperatively closed using a detachable endoloop and hemoclips: a case report. *Korean J Gastroenterol* 2013;61:97-102. **(corresponding author)**
211. Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behcet's disease. *Yonsei Med J* 2013;54:1084-1090. **(corresponding author)**
212. Moon CM, Shin DJ, Son NH, et al. Genetic variants in the IL12B gene are associated with inflammatory bowel diseases in the Korean population. *J Gastroenterol Hepatol* 2013;28:1588-1594. **(corresponding author)**
213. Moon CM, Shin DJ, Kim SW, et al. Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population. *Inflamm Bowel Dis* 2013;19:106-114. **(corresponding author)**
214. Lim YJ, Joo YS, Jung DY, et al. Learning curve of capsule endoscopy. *Clin Endosc* 2013;46:633-636.
215. Lim SM, Nam CM, Kim YN, et al. The effect of the menstrual cycle on inflammatory bowel disease: a prospective study. *Gut Liver* 2013;7:51-57. **(corresponding author)**
216. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. *Inflamm Bowel Dis* 2013;19:1833-1838. **(corresponding author)**
217. Kim YS, Han DS, Kim YH, et al. Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. *Epidemiol Infect* 2013;141:189-194.
218. Kim SW, Park KC, Jeon SM, et al. Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. *Cell Oncol (Dordr)* 2013;36:169-178. **(corresponding author)**
219. Kim DH, Cheon JH, Park JJ, et al. Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn's disease. *Gut Liver* 2013;7:58-65.
220. Kang HP, Lee H, Oh TG, et al. The use of health functional foods in gastrointestinal cancer patients. *Clin Nutr Res* 2013;2:19-25.
221. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. *Dig Dis Sci* 2013;58:496-503.
222. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Long-term clinical outcomes of Crohn's disease and intestinal Behcet's disease. *Inflamm Bowel Dis* 2013;19:99-105.
223. Jeon HH, Lee HJ, Jang HW, et al. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. *World J Gastroenterol* 2013;19:265-273. **(corresponding author)**
224. Chung SH, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH. Intestinal Behcet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis. *World J Gastroenterol* 2013;19:5389-5392.
225. Chung SH, Park SJ, Hong JS, et al. Comparison of double pants with single pants on satisfaction with colonoscopy.

World J Gastroenterol 2013;19:4177-4184.

226. Chung SH, Park SJ, Cheon JH, et al. Factors predictive of high-risk adenomas at the third colonoscopy after initial adenoma removal. *J Korean Med Sci* 2013;28:1345-1350.
227. Choi AR, Yoon JY, Lee HJ, et al. Clinical outcomes following secondary self-expandable metal stent (SEMS) insertion due to previous stent migration in malignant colorectal obstruction. *Surg Endosc* 2013;27:3288-3296. **(corresponding author)**
228. Cheon JH, Moon W, Park SJ, et al. [A case of intestinal tuberculosis with perianal fistula diagnosed after 30 years]. *Korean J Gastroenterol* 2013;62:370-374. **(1st author)**
229. Cheon JH, Hahm KB. Perfecting video capsule endoscopy: is there need for training? *Clin Endosc* 2013;46:599-600. **(1st author)**
230. Cheon JH. Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives. *J Gastroenterol Hepatol* 2013;28:220-226. **(1st author)**
231. Bok HJ, Lee JH, Shin JK, et al. [Clinicopathologic features of colorectal cancer combined with synchronous and metachronous gastric cancer]. *Korean J Gastroenterol* 2013;62:27-32.
232. Ye BD, Yang SK, Shin SJ, et al. [Guidelines for the management of Crohn's disease]. *Korean J Gastroenterol* 2012;59:141-179.
233. Park SJ, Cheon JH, Ye BD, et al. [A survey of actual clinical application patterns in Korean diagnostic guidelines for inflammatory bowel disease]. *Korean J Gastroenterol* 2012;60:292-299.
234. Park JJ, Cheon JH, Hong SP, Kim TI, Kim WH. Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease. *Dig Dis Sci* 2012;57:133-141.
235. Park JJ, Cheon JH. Malignant small bowel obstruction: the last frontier for gastrointestinal stenting. *J Gastroenterol Hepatol* 2012;27:1136-1137. **(corresponding author)**
236. Park H, Park JJ, Moon CM, et al. Diagnostic utility of computer tomographic enterography for patients presenting with unexplained gastrointestinal symptoms. *Hepatogastroenterology* 2012;59:1869-1873. **(corresponding author)**
237. Lee TH, Lee JS, Jo Y, et al. Superior mesenteric artery syndrome: where do we stand today? *J Gastrointest Surg* 2012;16:2203-2211.
238. Lee SK, Yang KM, Cheon JH, Kim TI, Kim WH. [Anti-inflammatory mechanism of *Lactobacillus rhamnosus* GG in lipopolysaccharide- stimulated HT-29 cell]. *Korean J Gastroenterol* 2012;60:86-93.
239. Lee JH, Yoon JY, Park SJ, et al. The learning curve for colorectal stent insertion for the treatment of malignant colorectal obstruction. *Gut Liver* 2012;6:328-333. **(corresponding author)**
240. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. *Int J Cancer* 2012;131:752-759.
241. Lee JH, Jeon SM, Hong SP, Cheon JH, Kim TI, Kim WH. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. *Dig Liver Dis* 2012;44:1042-1047.
242. Lee HJ, Kim YN, Jang HW, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. *World J Gastroenterol* 2012;18:5771-5778. **(corresponding author)**
243. Lee HJ, Jung ES, Lee JH, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. *Hepatogastroenterology* 2012;59:1415-1420. **(corresponding author)**
244. Lee DJ, Kim B, Lee JH, et al. [The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes]. *Korean J Gastroenterol* 2012;60:355-361.
245. Kim YS, Kim YH, Kim JS, et al. Cytomegalovirus infection in patients with new onset ulcerative colitis: a prospective study. *Hepatogastroenterology* 2012;59:1098-1101.
246. Kim YS, Kim YH, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. *J Clin Gastroenterol* 2012;46:51-56.
247. Kim SW, Kim ES, Moon CM, Kim TI, Kim WH, Cheon JH. Abnormal genetic and epigenetic changes in signal

transducer and activator of transcription 4 in the pathogenesis of inflammatory bowel diseases. *Dig Dis Sci* 2012;57:2600-2607. **(corresponding author)**

248. Kim JH, Oh SH, Kim EJ, et al. The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myeloid cells in the colorectal cancer microenvironment. *Biochem Biophys Res Commun* 2012;423:60-66.
249. Kim ES, Kim SW, Moon CM, et al. Interactions between IL17A, IL23R, and STAT4 polymorphisms confer susceptibility to intestinal Behcet's disease in Korean population. *Life Sci* 2012;90:740-746. **(corresponding author)**
250. Kim BK, Hong SP, Heo HM, et al. Endoscopic stenting is not as effective for palliation of colorectal obstruction in patients with advanced gastric cancer as emergency surgery. *Gastrointest Endosc* 2012;75:294-301.
251. Jung YS, Yoon JY, Hong SP, Kim TI, Kim WH, Cheon JH. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet's disease. *Inflamm Bowel Dis* 2012;18:1064-1071. **(corresponding author)**
252. Jung YS, Park JJ, Kim SW, et al. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. *Dig Liver Dis* 2012;44:897-903. **(corresponding author)**
253. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. *J Clin Gastroenterol* 2012;46:e38-45. **(corresponding author)**
254. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Early versus late surgery in patients with intestinal Behcet disease. *Dis Colon Rectum* 2012;55:65-71. **(corresponding author)**
255. Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. *Inflamm Bowel Dis* 2012;18:750-757.
256. Jang HW, Kim YN, Nam CM, et al. Factors affecting colonoscope insertion time in patients with or without a colostomy after left-sided colorectal resection. *Dig Dis Sci* 2012;57:3219-3225. **(corresponding author)**
257. Hur H, Kim NK, Kim HG, et al. Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. *Br J Cancer* 2012;106:53-60.
258. Hong SP, Min BS, Kim TI, et al. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. *Eur J Cancer* 2012;48:1235-1243.
259. Hong SP, Cheon JH, Kim TI, Song SY, Kim WH. Comparison of the diagnostic yield of "MiroCam" and "PillCam SB" capsule endoscopy. *Hepatogastroenterology* 2012;59:778-781.
260. Heo HM, Park CH, Lim JS, et al. The role of capsule endoscopy after negative CT enterography in patients with obscure gastrointestinal bleeding. *Eur Radiol* 2012;22:1159-1166.
261. Yoon JY, Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and risk factors for technical and clinical failures of self-expandable metal stent insertion for malignant colorectal obstruction. *Gastrointest Endosc* 2011;74:858-868. **(corresponding author)**
262. Yoon JY, Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Outcomes of secondary stent-in-stent self-expandable metal stent insertion for malignant colorectal obstruction. *Gastrointest Endosc* 2011;74:625-633. **(corresponding author)**
263. Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. *J Gastroenterol Hepatol* 2011;26:1114-1122.
264. Shin JK, Cheon JH, Lim JS, et al. Long-term outcomes of obscure gastrointestinal bleeding after CT enterography: does negative CT enterography predict lower long-term rebleeding rate? *J Gastroenterol Hepatol* 2011;26:901-907. **(corresponding author)**
265. Park JJ, Cheon JH, Kwon JE, et al. Clinical outcomes and factors related to resectability and curability of EMR for early colorectal cancer. *Gastrointest Endosc* 2011;74:1337-1346. **(corresponding author)**
266. Park JJ, Cheon JH. Small bowel evaluation in asymptomatic fecal immunochemical test-positive patients with a negative colonoscopy: is it necessary? *Dig Dis Sci* 2011;56:2773-2775. **(corresponding author)**
267. Park CH, Cheon JH, Kim JO, et al. Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. *Endoscopy* 2011;43:790-795.

268. Lee JH, Hong SP, Jeon TJ, et al. Should a colonoscopy be recommended for healthy individuals with increased carcinoembryonic antigen levels? A case-control study. *Dig Dis Sci* 2011;56:2396-2403.
269. Lee HJ, Hong SP, Cheon JH, et al. Long-term outcome of palliative therapy for malignant colorectal obstruction in patients with unresectable metastatic colorectal cancers: endoscopic stenting versus surgery. *Gastrointest Endosc* 2011;73:535-542.
270. Lee BI, Choi H, Choi KY, et al. Clinical characteristics of small bowel tumors diagnosed by double-balloon endoscopy: KASID multi-center study. *Dig Dis Sci* 2011;56:2920-2927.
271. Kim YS, Kim YH, Kim WH, et al. Diagnostic utility of anti-Saccharomyces cerevisiae antibody (ASCA) and Interferon-gamma assay in the differential diagnosis of Crohn's disease and intestinal tuberculosis. *Clin Chim Acta* 2011;412:1527-1532.
272. Kim SW, Kim ES, Moon CM, et al. Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease. *Gut* 2011;60:1527-1536. **(corresponding author)**
273. Kim JH, Kim YS, Cheon JH, et al. Influence of the insertion time and number of polyps on miss rate in colonoscopy. *Scand J Gastroenterol* 2011;46:634-639.
274. Kim BJ, Choi YS, Jang BI, et al. Prospective evaluation of the clinical utility of interferon-gamma assay in the differential diagnosis of intestinal tuberculosis and Crohn's disease. *Inflamm Bowel Dis* 2011;17:1308-1313.
275. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. *Inflamm Bowel Dis* 2011;17:1594-1602. **(corresponding author)**
276. Jung YS, Kim SW, Yoon JY, et al. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease. *Inflamm Bowel Dis* 2011;17:2130-2137. **(corresponding author)**
277. Jung ES, Kim SW, Moon CM, et al. Relationships between genetic polymorphisms of triggering receptor expressed on myeloid cells-1 and inflammatory bowel diseases in the Korean population. *Life Sci* 2011;89:289-294.
278. Jeon SM, Lee JH, Hong SP, Kim TI, Kim WH, Cheon JH. Feasibility of salvage endoscopic mucosal resection by using a cap for remnant rectal carcinoids after primary EMR. *Gastrointest Endosc* 2011;73:1009-1014. **(corresponding author)**
279. Jang HW, Cheon JH, Nam CM, et al. Factors affecting insertion time for colonoscopy performed under intramuscular analgesia in patients with history of colorectal resection. *Surg Endosc* 2011;25:2316-2322. **(corresponding author)**
280. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. *Inflamm Bowel Dis* 2011;17:605-613. **(1st author)**
281. Song HJ, Kim JY, Jung SA, et al. Effect of probiotic Lactobacillus (Lacidofil(R) cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study. *J Korean Med Sci* 2010;25:1784-1791.
282. Shin SJ, Lee SK, Kim TI, et al. Chronological changes in the systemic manifestations of intestinal Behcet's disease and their significance in diagnosis. *Int J Colorectal Dis* 2010;25:1371-1376.
283. Shin JK, Cheon JH, Kim ES, et al. Predictive capability of anorectal physiologic tests for unfavorable outcomes following biofeedback therapy in dyssynergic defecation. *J Korean Med Sci* 2010;25:1060-1065. **(corresponding author)**
284. Park S, Cheon JH, Park JJ, et al. Comparison of efficacies between stents for malignant colorectal obstruction: a randomized, prospective study. *Gastrointest Endosc* 2010;72:304-310. **(corresponding author)**
285. Park JJ, Cheon JH, Kim HM, et al. Negative capsule endoscopy without subsequent enteroscopy does not predict lower long-term rebleeding rates in patients with obscure GI bleeding. *Gastrointest Endosc* 2010;71:990-997. **(corresponding author)**
286. Park JH, Byeon JS, Shin WG, et al. [Diagnosis of irritable bowel syndrome: a systematic review]. *Korean J Gastroenterol* 2010;55:308-315.
287. Park HN, Park JJ, Cheon JH, et al. [Nonrotation of the prearterial segment of midgut presenting as duodenal obstruction in a 60-year-old man]. *Korean J Gastroenterol* 2010;55:252-255.
288. Moon CM, Cheon JH, Shin JK, et al. Prediction of free bowel perforation in patients with intestinal Behcet's disease

using clinical and colonoscopic findings. *Dig Dis Sci* 2010;55:2904-2911. **(corresponding author)**

289. Moon CM, Cheon JH, Kim SW, et al. Association of signal transducer and activator of transcription 4 genetic variants with extra-intestinal manifestations in inflammatory bowel disease. *Life Sci* 2010;86:661-667. **(corresponding author)**
290. Moon CM, Cheon JH, Choi EH, et al. Advanced synchronous adenoma but not simple adenoma predicts the future development of metachronous neoplasia in patients with resected colorectal cancer. *J Clin Gastroenterol* 2010;44:495-501. **(corresponding author)**
291. Lee JM, Cheon JH, Park JJ, et al. Effects of Hyosine N-butyl bromide on the detection of polyps during colonoscopy. *Hepatogastroenterology* 2010;57:90-94. **(corresponding author)**
292. Lee JH, Cheon JH, Moon CM, et al. Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older? *Digestion* 2010;81:237-243. **(corresponding author)**
293. Lee JH, Cheon JH, Kim ES, et al. The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis. *Dig Dis Sci* 2010;55:1406-1412. **(corresponding author)**
294. Kim YJ, Cheon JH, Lee SK, Kim JH, Lee YC. Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study. *J Korean Med Sci* 2010;25:583-588. **(corresponding author)**
295. Kim SW, Kim HM, Yang KM, et al. Bifidobacterium lactis inhibits NF-kappaB in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice. *Inflamm Bowel Dis* 2010;16:1514-1525. **(corresponding author)**
296. Kim SG, Song HJ, Choi IJ, et al. A Planned Prospective, Randomized, Placebo-Controlled Multicenter Trial Assessing the Effect of Helicobacter pylori Eradication on the Healing of Iatrogenic Ulcer after Endoscopic Resection of Gastric Neoplasm. *Gut Liver* 2010;4:514-517.
297. Kim JH, Cheon JH, Hong SS, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. *J Clin Gastroenterol* 2010;44:e242-248.
298. Kim HM, Kim YJ, Kim HJ, et al. A Pilot Study of Sequential Capsule Endoscopy Using MiroCam and PillCam SB Devices with Different Transmission Technologies. *Gut Liver* 2010;4:192-200.
299. Kim ES, Cheon JH, Park JJ, et al. Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: focus on pain perception. *J Gastroenterol Hepatol* 2010;25:1232-1238. **(corresponding author)**
300. Jung YS, Cheon JH, Park JJ, et al. Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. *J Hum Genet* 2010;55:121-123. **(corresponding author)**
301. Jung KS, Park JJ, Chon YE, et al. Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea. *Gut Liver* 2010;4:332-337. **(corresponding author)**
302. Jang BI, Lee SH, Moon JS, et al. Inter-observer agreement on the interpretation of capsule endoscopy findings based on capsule endoscopy structured terminology: a multicenter study by the Korean Gut Image Study Group. *Scand J Gastroenterol* 2010;45:370-374.
303. Chung MJ, Cheon JH, Kim SU, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behcet disease. *J Clin Gastroenterol* 2010;44:e116-122. **(corresponding author)**
304. Chung JW, Cheon JH, Park JJ, Jung ES, Choi EH, Kim H. Development and validation of a novel prognostic scoring model for ischemic colitis. *Dis Colon Rectum* 2010;53:1287-1294. **(corresponding author)**
305. Chung JW, Cheon JH, Lee KJ, et al. [Aplastic anemia with trisomy 8 and trisomy 9 in intestinal behcets disease]. *Korean J Gastroenterol* 2010;55:256-260.
306. Cheung DY, Lee IS, Chang DK, et al. Capsule endoscopy in small bowel tumors: a multicenter Korean study. *J Gastroenterol Hepatol* 2010;25:1079-1086.
307. Yi SW, Cheon JH, Kim JH, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behcet's disease: a single center experience in Korea. *J Korean Med Sci* 2009;24:52-56. **(corresponding author)**

308. Shin DY, Cheon JH, Park JJ, et al. [Serial episodes of gastric and cecal perforation in a patient with Behcet's disease involving the whole gastrointestinal tract: a case report]. *Korean J Gastroenterol* 2009;53:106-110. **(corresponding author)**
309. Park JJ, Cheon JH, Kim BY, et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. *Dig Dis Sci* 2009;54:1525-1531. **(corresponding author)**
310. Kim JH, Lee YC, Kim H, et al. Endoscopic resection for undifferentiated early gastric cancer. *Gastrointest Endosc* 2009;69:e1-9.
311. Kim DH, Cheon JH, Moon CM, et al. [Clinical efficacy of nonsurgical treatment of Crohn's disease-related intraabdominal abscess]. *Korean J Gastroenterol* 2009;53:29-35. **(corresponding author)**
312. Cheon JH, Shin SJ, Kim SW, Lee KM, Kim JS, Kim WH. [Diagnosis of intestinal Behcet's disease]. *Korean J Gastroenterol* 2009;53:187-193. **(1st author)**
313. Cheon JH, Kim JH, Kim BY, et al. Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases. *Hepatogastroenterology* 2009;56:421-423. **(1st author)**
314. Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet's disease in Korean patients with ileocolonic ulcers. *Am J Gastroenterol* 2009;104:2492-2499. **(1st author)**
315. An MJ, Cheon JH, Kim SW, et al. Bovine colostrum inhibits nuclear factor kappaB-mediated proinflammatory cytokine expression in intestinal epithelial cells. *Nutr Res* 2009;29:275-280. **(corresponding author)**
316. An MJ, Cheon JH, Kim SW, Kim ES, Kim TI, Kim WH. Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. *Cancer Lett* 2009;279:93-100. **(corresponding author)**
317. Woo HG, Park ES, Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. *Clin Cancer Res* 2008;14:2056-2064.
318. Park SY, Lee SK, Kim BC, et al. Efficacy of chromoendoscopy with indigocarmine for the detection of ascending colon and cecum lesions. *Scand J Gastroenterol* 2008;43:878-885.
319. Park JJ, Cheon JH. [Intestinal tuberculosis mimicking colon cancer]. *Korean J Gastroenterol* 2008;52:203-206. **(corresponding author)**
320. Lee SH, Cheon JH, Kim JH, Park JP, Lee SK, Lee YC. [Non-healing iatrogenic gastric ulcers after endoscopic mucosal resection for gastric epithelial neoplasia: report of two cases]. *Korean J Gastroenterol* 2008;51:127-131. **(corresponding author)**
321. Kim YJ, Lee SK, Cheon JH, et al. [Efficacy of endoscopic resection for small rectal carcinoid: a retrospective study]. *Korean J Gastroenterol* 2008;51:174-180.
322. Kim JH, Cheon JH, Park S, et al. Relationship between disease location and age, obesity, and complications in Korean patients with acute diverticulitis: a comparison of clinical patterns with those of Western populations. *Hepatogastroenterology* 2008;55:983-986. **(corresponding author)**
323. Kim JH, Cheon JH, Kim WH. [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease]. *Korean J Gastroenterol* 2008;51:291-297.
324. Kim JH, Cheon JH, Kim TI, et al. Effectiveness of radical surgery after incomplete endoscopic mucosal resection for early colorectal cancers: a clinical study investigating risk factors of residual cancer. *Dig Dis Sci* 2008;53:2941-2946. **(corresponding author)**
325. Kim ES, Hong SY, Lee HK, et al. Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells. *Oncol Rep* 2008;20:1321-1327. **(corresponding author)**
326. Kim BC, Cheon JH, Lee SK, Kim TI, Kim H, Kim WH. Needle knife-assisted endoscopic polypectomy for a large inflammatory fibroid colon polyp by making its stalk into an omega shape using an endoloop. *Yonsei Med J* 2008;49:680-686. **(corresponding author)**
327. Kim BC, Cheon JH, Kim TI, Kim WH. Risk factors and the role of bedside colonoscopy for lower gastrointestinal hemorrhage in critically ill patients. *Hepatogastroenterology* 2008;55:2108-2111. **(corresponding author)**
328. Han JY, Cheon JH, Kim DH, et al. [Ileal mucormycosis diagnosed by colonoscopy in a patient with acute myeloid

leukemia]. Korean J Gastroenterol 2008;52:179-182. **(corresponding author)**

329. Cheon JH, Kim JH, Lee SK, Kim TI, Kim WH, Lee YC. Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study. Helicobacter 2008;13:564-571. **(1st author)**
330. Baik SH, Lee WJ, Rha KH, et al. Robotic total mesorectal excision for rectal cancer using four robotic arms. Surg Endosc 2008;22:792-797.
331. Kim SU, Cheon JH, Lim JS, et al. [Massive gastrointestinal bleeding due to aneurysmal rupture of ileo-colic artery in a patient with Behcet's disease]. Korean J Gastroenterol 2007;49:400-404. **(corresponding author)**
332. Kim JS, Chung SJ, Choi YS, et al. Helicobacter pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer 2007;96:1324-1328.
333. Kim JH, Song KS, Youn YH, et al. Clinicopathologic factors influence accurate endosonographic assessment for early gastric cancer. Gastrointest Endosc 2007;66:901-908.
334. Cheon JH, Song HJ, Kim JS, et al. Recurrent lower gastrointestinal bleeding from congenital arteriovenous malformation in the terminal ileum mimicking intestinal varicosis: a case report. J Korean Med Sci 2007;22:746-749. **(1st author)**
335. Cheon JH, Kim YS, Lee IS, et al. Can we predict spontaneous capsule passage after retention? A nationwide study to evaluate the incidence and clinical outcomes of capsule retention. Endoscopy 2007;39:1046-1052. **(1st author)**
336. Cheon JH, Kim WH. Recent advances of endoscopy in inflammatory bowel diseases. Gut Liver 2007;1:118-125. **(1st author)**
337. Cheon JH, Kim JS, Ko SJ, et al. Risk factors for upper gastrointestinal rebleeding in critically ill patients. Hepatogastroenterology 2007;54:766-769. **(1st author)**
338. Ye BD, Cheon JH, Choi KD, et al. Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. Aliment Pharmacol Ther 2006;24:837-843.
339. Chung GE, Cheon JH, Lee JY, et al. [Efficacy of combination of intravenous cyclosporin A and steroid therapy versus prolonged intravenous steroid therapy alone in patients with severe ulcerative colitis refractory to initial intravenous steroid therapy]. Korean J Gastroenterol 2006;48:263-268.
340. Choi YS, Cheon JH, Lee JY, et al. [The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years]. Korean J Gastroenterol 2006;48:156-161.
341. Cheon JH, Kim SG, Kim JM, et al. Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility. J Gastroenterol Hepatol 2006;21:1590-1595. **(1st author)**
342. Cheon JH, Kim N, Lee DH, et al. Long-term outcomes after Helicobacter pylori eradication with second-line, bismuth-containing quadruple therapy in Korea. Eur J Gastroenterol Hepatol 2006;18:515-519. **(1st author)**
343. Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006;11:46-51. **(1st author)**
344. Cheon JH, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis. Inflamm Bowel Dis 2006;12:1152-1161. **(1st author)**
345. Lee JH, Cheon JH, Park MJ, et al. [The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years]. Korean J Gastroenterol 2005;46:94-98.
346. Cho SH, Cheon JH, Lee SW, et al. [A case of osteoclast-like giant cell tumor of the pancreas]. Korean J Gastroenterol 2005;45:441-445.
347. Cheon JH, Kim N, Lee DH, et al. [Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection]. Korean J Gastroenterol 2005;45:111-117. **(1st author)**
348. Yoo SJ, Cheon JH, Lee SW, et al. [Extrahepatic metastasis of hepatocellular carcinoma to the nasal cavity manifested

as massive epistaxis: a case report]. Korean J Hepatol 2004;10:228-232.

349. Hwang JH, Yoon YB, Kim YT, Cheon JH, Jeong JB. Risk factors for recurrent cholangitis after initial hepatolithiasis treatment. J Clin Gastroenterol 2004;38:364-367.
350. Cheon JH, Park JW, Park KW, et al. [The clinical report of 1,078 cases of hepatocellular carcinomas: National Cancer Center experience]. Korean J Hepatol 2004;10:288-297. **(1st author)**

Honors & Awards

- 2005 The best paper award, The Korean Society of Hepatology
- 2006 The best paper award, The Korean Association for the Study of Intestinal Diseases
- 2007 Janssen award, The Korean Society of Gastroenterology
- 2007 The best professor of the year (clinical field), Yonsei University College of Medicine
- 2008 Academic award, Internal Medicine, Yonsei University College of Medicine
- 2010 Academic award, The Korean Association for the Study of Intestinal Diseases
- 2010 Hamchoon Academic award, Internal Medicine, Seoul National University College of Medicine
- 2011 Young investigator award, Yonsei University College of Medicine
- 2011 Distinguished Professor of the Year (Research field), Yonsei University
- 2012 Distinguished Professor of the Year (Clinical research field), Yonsei University College of Medicine
- 2012 Asian-Pacific Gastroenterology Association, Award of Emerging Leadership Lecturer
- 2012 The best prolific award, Internal Medicine, Yonsei University College of Medicine
- 2012 Outstanding results in basic research field from Ministry of Education
- 2014 Distinguished Professor of the Year (Education field), Yonsei University College of Medicine
- 2014 Best professor for referral patient treatment
- 2014 Academic award-grand for correspondence author, Internal Medicine, Yonsei University College of Medicine
- 2017 50th Yuhan Medical Award Grand Prize
- 2018 The best research award, Korean FDA research and development exhibition
- 2020 Professor of the Year 2020, Department of Internal Medicine, Yonsei University College of Medicine